GANA HA body

Name: GANA HA body
Brand: GANA R&D

A 50 ml prefilled vial of cross-linked hyaluronic acid (20 mg/cc, 10 % cross-linking) made for body contouring, with removal by hyaluronidase and a short, minimally invasive procedure.

01 概览

Hyaluronic acid dermal filler for body contouring

规格50 ml prefilled vial; withdraw into 10 ml syringes (five syringes per vial)
成分
- Cross-linked hyaluronic acid 20 mg/cc
- Cross-linking ratio 10 %
- Particle size 500 µm
成分类别Hyaluronic acid
注册1 项有效 · 俄罗斯
产品目录2026 年 GANA R&D 产品目录，第 23–27 页

产品详情以 GANA R&D 产品目录发布的英文版显示。

索取产品资料

GANA HA body — carton and 50 ml prefilled vial

02 有据可查

本产品的注册信息

每一项注册均以 GANA R&D 为制造商，所有编号均可在主管机构的公开登记系统中核查。

注册名称	司法管辖区	注册	授予日期	范围	核查
GANA HA Body	俄罗斯 · Roszdravnadzor	РЗН 2022/18121	2022年8月29日	—	公开登记→

俄罗斯 Roszdravnadzor 登记系统使用俄罗斯国家颁发的证书，俄罗斯境外的浏览器在打开记录前可能会显示安全警告。

制造商

MFDS 制造业许可GANA R&D Co., Ltd. · MFDS No. 4490 · 公开登记→
GMP 证书KCL-ABBA-19926 · 有效期至 2027年3月3日
生产场所555 Dunchon-daero, Jungwon-gu, Seongnam-si 13215, Republic of Korea

03 摘自产品目录

产品详情

转载自 2026 年 GANA R&D 产品目录。仅供医疗专业人员参考；本说明不能替代随产品提供的使用说明书。

HA filler for body augmentation

GANA HA body is a dermal filler made specifically for body contouring, for example breast augmentation and buttock augmentation. It is a monophasic HA filler with the same characteristics as GANA HA.

No addition of non-cross-linked HA
Highest cross-linking ratio
Highest HA concentration
Small particle size, so the shape is easy to mould
Higher viscosity than other dermal fillers
Longest duration
Low extrusion force

Merits of HA filler for body augmentation

	Removal	Price	Safety	Procedure time	Minimally invasive
HA dermal fillers	Yes	Expensive	Yes	Long	Yes
Conventional fillers (PMMA, PAAG)	No	Expensive	Partly	Short	Yes
Implants	Yes, but major surgery	Expensive	Partly	Long	No
GANA HA body	Yes	Reasonable	Yes	Short	Yes

GANA HA body compared with existing HA fillers

	Monophasic	Biphasic	GANA HA body
Cross-linking ratio	6 %	1–2 %	10 %
HA concentration (mg/cc)	20–24	20–24	20
Cross-linking agent	BDDE	BDDE	BDDE
Duration (months)	6–12	6–18	24
Particle size	None	100–2000 µm	500 µm
Viscosity (cPs)	2–4 × 10⁶	1–4 × 10⁶	2–4 × 10⁶
Package size	1–3 ml	1–3 ml	50 ml

Specification

Test item	Standard	Result
Appearance	Colourless, transparent; no visible foreign matter, no air bubbles	Qualified
Hyaluronate content	20 mg/ml	Qualified
pH	6.5–7.5	7.3
Osmotic pressure (mOsmol/L)	0.9–1.1	1
Particle size distribution	Body: 500 µm, 23 G	Qualified
Cross-linking agent (BDDE) residue	≤ 2.0 µg/g	Qualified
Protein	≤ 0.1 %	Qualified
Heavy metals	≤ 20 ppm	Qualified
Bacteria test	No bacterial growth	Qualified
Bacterial endotoxin test	≤ 0.5 EU/mL	Qualified
Viscosity	2–4 × 10⁶ cPs	Qualified
Haemolysis	No haemolysis ring	Qualified

The products were tested in conformity with the GANA R&D standard.

How to use

Remove the aluminium cap and rubber stopper.
Withdraw GANA HA body with a 10 cc syringe: five syringes per vial.
Anaesthetise the puncture site.
Puncture with a 16 G or 18 G needle.
Attach a 16 G or 18 G cannula to the prefilled 10 ml syringe.
Inject GANA HA body into the breast or hip. In the hip the injection area is the subcutaneous fat layer; in the breast, just above the pectoralis major muscle, taking care not to damage the mammary glands.
For each breast or hip the minimum dose is 50 ml; the maximum dose per breast is 200 ml.

How to withdraw: GANA HA body is a prefilled vial with high viscosity and needs a special technique. Prepare normal saline, an 18 G needle and six 10 ml syringes; open the caps of the saline and the body vial, withdraw 10 ml of normal saline, mix it with the body vial, and the product can then be withdrawn easily.

Progress after the procedure

For 3–4 days there may be swelling and pain.
Prescribe a painkiller, antibiotics and an anti-inflammatory for 5 days.
Swelling and pain are normal: with a cross-linking ratio of almost 10 % the product absorbs water and enlarges for a few days.
A second session within a month is necessary. The injected filler can migrate to adjacent areas, so the practitioner corrects the shape in the second session.